Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive inotropic agent labeling should discuss risks of long-term use in CHF -- FDA advisory committee.

Executive Summary

POSITIVE INOTROPIC AGENT LABELING SHOULD DISCUSS RISKS OF LONG- TERM CHF USE FDA's Cardiovascular & Renal Advisory Committee unanimously agreed at its Jan. 27 meeting. The committee voted 10-0 with one abstention that labeling of approved I.V. positive inotropic agents for congestive heart failure be revised along the lines of language proposed by FDA that "experience with intravenous in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. In a multicenter trial of oral , long-term use was associated with an increased risk of hospitalization and death, and patients with NYHA Class IV symptoms appeared to be at particular risk."

You may also be interested in...

Tysabri Return Depends On Patient Group Input, CDER Deputy Says

FDA will rely on the input of multiple sclerosis patient organizations to help determine the status of Biogen Idec/Elan's Tysabri, Center for Drug Evaluation & Research Acting Deputy Director Douglas Throckmorton told the Stanford Washington Research Group conference May 5

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts